Maropitant
From Wikipedia, the free encyclopedia
 |
|
|
Maropitant
|
|
| Systematic (IUPAC) name | |
| (7R,8S)-N-[(5-tert-Butyl-2-methoxyphenyl)methyl]-7-[di(phenyl)methyl]-1-azabicyclo[2.2.2]octan-8-amine | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C32H40N2O |
| Mol. mass | 468.67 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
veterinary prescription only |
| Routes | Oral, subcutaneous |
Maropitant, also known as maropitant citrate (USAN) is a neurokinin (NK1) receptor antagonist, which was developed by Pfizer Animal Health specifically for the treatment of motion sickness and vomiting in dogs and cats.
It is marketed under the brand name Cerenia, and was approved for use on February 2007.[1]
[edit] References
[edit] External links
 |
This veterinary medicine related article is a stub. You can help by expanding it. |
